Clinical Trials
3
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Phase 1
- Conditions
- Locally Advanced Solid TumorMetastatic Solid TumorHematologic Malignancies
- Interventions
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- Curon Biopharmaceutical (Australia) Co Pty Ltd
- Target Recruit Count
- 164
- Registration Number
- NCT05028478
A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies
Phase 1
Terminated
- Conditions
- Relapsed Lymphoid MalignanciesRefractory Lymphoid Malignancies
- Interventions
- Drug: CN1, 0.5mg/kg and CN401, 400mgDrug: CN1, 1mg/kg and CN401, 800mgDrug: CN1, 10mg/kg and CN401, 800mgDrug: CN1, 1mg/kg and CN401, 600mgDrug: CN1, 3mg/kg and CN401, 800mg
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Curon Biopharmaceutical (Australia) Co Pty Ltd
- Target Recruit Count
- 7
- Registration Number
- NCT04880564
- Locations
- 🇦🇺
Monash Health - Monash Medical Centre, Bentleigh, Victoria, Australia
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Curon Biopharmaceutical (Australia) Co Pty Ltd
- Target Recruit Count
- 13
- Registration Number
- NCT04418141
- Locations
- 🇦🇹
Mater Medical Centre, Brisbane, Queensland, Austria
News
No news found